Abstract: An embodiment provides a method for treating a body fluid of a patient with Covid-19, including: removing the body fluid from a patient; applying a treatment to the body fluid, wherein the treatment comprises an antibody that joins with a virion in the body fluid to form an antibody-virion complex, wherein the antibody comprises a tag sensitive to an illumination; removing the antibody-virion complex from the body fluid using an illumination source; and returning the body fluid to the patient. Other aspects are described and claimed.

Abstract: An embodiment provides a method for treating a body fluid of a patient with an inflammatory cytokine storm, including: removing the body fluid from a patient; applying a treatment to the body fluid, wherein the treatment comprises an antibody that joins with an antigen in the body fluid to form an antibody -antigen complex; removing the antibody-antigen complex from the body fluid; and returning the body fluid to the patient. Other aspects are described and claimed.

Abstract: An embodiment provides a method for treating a body fluid, including: removing the body fluid from a patient; applying a treatment to the body fluid, wherein the treatment comprises an antibody that joins with an antigen in the body fluid to form an antibody-antigen complex; removing the antibody-antigen complex from the body fluid; and returning the body fluid to the patient. Other aspects are described and claimed.

Abstract: An embodiment provides a compound for treatment of Covid-19 in a patient, including: a dose comprising: an amount of naltrexone; an amount of vitamin D; an amount of melatonin; and an amount of zinc picolinate in a dose. Other aspects are described and claimed.

Abstract: An embodiment provides a method for treating a body fluid of a patient with Covid-19, including: removing the body fluid from a patient, wherein the body fluid comprises a Covid-19 targeted pathogenic antigen (TPA); applying a treatment to the body fluid, wherein the treatment comprises an antibody that joins with the Covid-19 targeted pathogenic antigen in the body fluid to form an antibody-TPA complex, wherein the antibody comprises a radiofrequency absorption enhancer forming an antibody-radio frequency enhancing moiety-virion complex (ARFVC); removing the ARFVC from the body fluid using a radiofrequency source; and returning the body fluid to the patient. Other aspects are described and claimed.

Abstract: An embodiment provides a method for preventing the transmission of Covid-19, including: preparing a composition comprising an ACE2 monoclonal antibody, a Neuropilin-1 antibody, an antibody to the spike protein of Sars-CoV-2, a vegetable oil, and a saline solution; and spraying the composition in a nasal cavity of a patient. Other aspects are described and claimed.

Abstract: An embodiment provides a method for preventing the transmission of Covid-19, including: preparing a composition comprising an ACE2 monoclonal antibody, a vegetable oil, and a saline solution; and spraying the composition in a nasal cavity of a patient. Other aspects are described and claimed.

Abstract: An embodiment provides a method for identifying Covid-19 in a body fluid of a patient, including: removing the body fluid from a patient; applying a treatment to the body fluid, wherein the treatment comprises an antibody that joins with a Covid-19 targeted antigen (TA) in the body fluid to form an antibody-TA complex, wherein the antibody comprises a light functional antibody; identifying the antibody-TA complex, using a spectroscopic technique, from the body fluid using a light source; and returning the body fluid to the patient. Other aspects are described and claimed.

Abstract: Disclosed is a method for treating of Cockayne Syndrome (CS). Specifically, the invention pertains to a method for the extracorporeal treatment of a body fluid by removing the body fluid from a living body diseased with CS, and applying a targeted antibody either a mammalian target of rapamycin (mTOR) antigen or a death-associated protein 1 (DAP1) in a bodily fluid such as blood, creating an antibody-antigen complex, removing antibody-antigen complex from the bodily fluid, and returning the purified bodily fluid to the CS patient.

Abstract: Disclosed is a method for treating of Cockayne Syndrome (CS). Specifically, the invention pertains to a method for the extracorporeal treatment of a body fluid by removing the body fluid from a living body diseased with CS, and applying a targeted antibody either a mTOR antigen or a DAP1 in a bodily fluid such as blood, creating an antibody-antigen complex, removing antibody-antigen complex from the bodily fluid, and returning the purified bodily fluid to the CS patient.

Abstract: A method is described to treat atherosclerosis by extracorporeally treating a patient's blood. A patient's blood is treated extracorporeally using a moiety that targets an antigen in the blood. The moiety facilitates removal of the blood antigen. The cleansed blood is then returned to the patient.

Abstract: Disclosed is a method for treating of Cockayne Syndrome (CS). Specifically, the invention pertains to a method for the extracorporeal treatment of a body fluid by removing the body fluid from a living body diseased with CS, and applying a targeted antibody conjugated to a moiety to at least one Cockayne Syndrome antigen in the body fluid, creating an antibody-antigen moiety complex, removing antibody-antigen moiety complex from the body fluid, and returning the purified body fluid to the body.

Abstract: The present invention relates to the treatment of cancers. Specifically, the invention pertains to a method for the extracorporeal treatment of one or more body fluids (e.g., blood or cerebrospinal fluid, CSF) in two stages characterized by removing a body fluid (e.g., blood or CSF) from a living body diseased with a type of cancer, passing the body fluid through a first stage of applying a treatment to at least one antigen in the body fluid. More specifically, the treatment comprises creating an antibody-antigen moiety during passage thereof through said first stage, passing the treated body fluid through a second stage, removing antibody-antigen moiety from the body fluid during passage through the second stage, and returning the purified body fluid to the body.

Abstract: The present invention relates to the treatment of infectious diseases, specifically by extracorporeally eradicating the pathogen. This invention comprises methods for the extracorporeal treatment of infectious diseases that will remove infectious pathogens (leukemia cells, bacteria, viruses, or fungi causing a septicemia, metastatic cancer cells, target protein, viruses, parasites, fungi and prions) in humans by targeting such pathogens with a laser or other high-energy source of emissive radiation. More specifically, the method involves removing a bodily fluid from a patient, attaching an antibody to pathogens in the bodily fluid, sensing the antibody-pathogen moiety, using a high-powered, focused laser, or other suitable light source, to destroy the antibody-pathogen moiety, removing the remains of the antibody-pathogen by filtering or other suitable mechanism(s), and returning the bodily fluid to the patient.

Abstract: A method is described to treat chronic pain syndromes by treating extracorporeally a patient's cerebrospinal fluid (CSF). A patient's CSF is treated extracorporeally using a moiety that targets an antigen in the CSF. This moiety facilitates removal of the CSF antigen. The cleansed CSF is then returned to the patient.

Abstract: A method for treating muscular dystrophy is described, including extracorporeally treating a patient's bodily fluid. The bodily fluid is removed from a patient before treatment and returned to the patient after treatment. The treatment targets an antigen associated with muscular dystrophy, such as interleukin-17 (IL-17), TNF-? (tumor necrosis factor-alpha), interleukin-6 (IL-6), CTGF-? (transforming growth factor-beta), MCP-1 (monocyte chemotactic protein-1), and combinations thereof. The treatment removes the antigen from the bodily fluid. Preferably, the treatment is removed from the bodily fluid before returning to the patient.

Abstract: A method of slowing the aging process by extracorporeally treating a patient's blood is described. Certain antigens are known to be associated with aging. The method targets these antigens by complexing them with chemicals that facilitate removal of the antigens from the blood. The blood is removed from the patient, treated with a complexing agent, and then removed from the extracorporeal blood before the blood is returned to the patient. Targeted antigens can include mTOR (mammalian target of rapamycin), insulin growth factor-1 (IGF-1, insulin-like growth factor-1, somatomedin C), lipofuscin, p16 (p16INK4a, CDKN2A, cyclin-dependent kinase inhibitor 2A), SA-beta-gal (senescence-associated beta-gal), PML (promyelocytic leukemia) protein, TGF-? (transforming growth factor-beta), interleukin-6 (IL-6), indoleamine 2,3-dioxygenase, sTNF-R55 (soluble tumor necrosis factor-receptor 55), sTNF-R75 (soluble tumor necrosis factor-receptor 75), progerin, oxygen free radicals (e.g.

Abstract: The present invention relates to the treatment of infectious diseases, specifically by extracorporeally eradicating the pathogen. This invention comprises methods for the extracorporeal treatment of infectious diseases that will remove infectious pathogens (leukemia cells, bacteria, viruses, or fungi causing a septicemia, metastatic cancer cells, target protein, viruses, parasites, fungi and prions) in humans by targeting such pathogens with a laser or other high-energy source of emissive radiation. More specifically, the method involves removing a bodily fluid from a patient, attaching an antibody to pathogens in the bodily fluid, sensing the antibody-pathogen moiety, using a high-powered, focused laser, or other suitable light source, to destroy the antibody-pathogen moiety, removing the remains of the antibody-pathogen by filtering or other suitable mechanism(s), and returning the bodily fluid to the patient.

Abstract: An article and method to treat extracorporeally a patient's bodily fluid. The bodily fluid can include blood, cerebral spinal fluid and lymph. A first stage of the method includes applying a treatment. The treatment can comprise dosing with a medication, thermal treatment, or irradiation. The treatment can occur at levels that could otherwise compromise the patient's health. A second stage of the method substantially removes the treatment from the bodily fluid. The bodily fluid can then be returned to the patient. The article includes a treatment chamber that applies the treatment and a removal module for removing the treatment. The method can be a continuous process such as, for example, a dialysis process.

Abstract: The present invention is directed to methods for treating cancer by administering an anti-CTLA-4 agent in combination with a metronomic chemotherapy or a sequential chemotherapy.